文献速递消化系统肿瘤

西妥昔单抗每两周方案一线治疗RAS野生型转移性结直肠癌非劣效于每周方案

Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2020-12-28

该汇总分析纳入上市后研究中接受一线西妥昔单抗联合化疗的RAS野生型转移性结直肠癌患者,比较每两周500 mg/m2与每周标准剂量方案的疗效。经IPTW调整后,每两周组OS非劣效于每周组(HR 0.827,95%CI 0.715-0.956),中位OS分别为27.9个月和24.7个月;PFS无显著差异,ORR和肺/肝转移灶切除率 favoring 每两周方案,严重不良事件发生率无差异。

要点

  • 每两周西妥昔单抗500 mg/m2一线治疗RAS野生型mCRC的OS非劣效于每周方案。
  • 每两周组中位OS 27.9个月,每周组24.7个月,HR 0.827(95%CI 0.715-0.956)。
  • PFS无显著差异,ORR和肺/肝转移灶切除率 favoring 每两周方案。

核心结论

  • 每两周西妥昔单抗方案一线治疗RAS野生型mCRC在OS上非劣效于每周方案。

研究设计与样本

  • 汇总分析纳入上市后研究中接受一线西妥昔单抗联合化疗的RAS野生型mCRC患者,Q2W组554例,Q1W组763例。
  • 采用倾向评分逆概率治疗加权(IPTW)调整基线特征,以HR非劣效界值1.25检验OS非劣效性。

主要发现

  • IPTW后OS的HR为0.827(95%CI 0.715-0.956),中位OS Q1W组24.7个月,Q2W组27.9个月。
  • PFS的HR为0.915(95%CI 0.804-1.042)。
  • ORR的IPTW后OR为1.292(95%CI 1.031-1.617),肺/肝转移灶切除率的OR为1.419(95%CI 1.043-1.932),均 favoring Q2W。
  • 任何严重不良事件发生率的IPTW后OR为1.089(95%CI 0.858-1.382),组间无差异。

临床怎么用

  • 对于一线接受西妥昔单抗联合化疗的RAS野生型mCRC患者,每两周500 mg/m2方案可作为每周方案的替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This study assessed whether cetuximab 500 mg/m2 administered every 2 weeks (Q2W), when combined with chemotherapy as a first-line (1L) treatment, was noninferior to the approved dose (400 mg/m2 followed by 250 mg/m2 once weekly [Q1W]) for overall survival (OS) in adults with RAS wild-type metastatic colorectal cancer (mCRC). METHODS: This pooled analysis included patients receiving 1L treatment with cetuximab Q1W or Q2W in combination with chemotherapy from post-authorisation studies with patient-level data available to the sponsor. Baseline characteristics were adjusted with a propensity score using inverse probability of treatment weighting (IPTW). Noninferiority in terms of OS was tested with a noninferiority margin for the hazard ratio (HR) of 1.25 using a Cox proportional hazards regression model. Secondary outcomes were progression-free survival (PFS), overall response rate (ORR) and rates of lung/liver metastases resection and serious adverse events. RESULTS: OS time was noninferior in the Q2W cohort (n = 554) compared to the Q1W cohort (n = 763), with a HR after IPTW (95% confidence interval) of 0.827 (0.715-0.956) and median OS times of 24.7 (Q1W) and 27.9 (Q2W) months. There were no major differences in PFS (HR: 0.915 [0.804-1.042]). The odds ratios (ORs) after IPTW for ORR (1.292 [1.031-1.617]) and the rates of lung/liver metastases resection (1.419 [1.043-1.932]) favoured the Q2W regimen. No differences were noted in the occurrence rate of any SAE between groups; the OR after IPTW was 1.089 (0.858-1.382). CONCLUSIONS: The cetuximab Q2W regimen was noninferior to the Q1W regimen for OS in the 1L treatment of mCRC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kasper S, Foch C, Messinger D, et al. Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2020. PMID: 33383349. doi:10.1016/j.ejca.2020.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。